JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Akciju saraksts・Sanofi

Sanofi

Slēgts

43.37 0.18

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

43.08

Max

43.52

Galvenie mērījumi
By Trading Economics
Ienākumi	2.4B 1.6B
Pārdošana	-961M 11B
P/E Sektora vidējais	19.885 67.147
EPS	1.102
Peļņas marža	14.354
Darbinieki	74,846
EBITDA	-1.1B 2.7B

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+22.26% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-11B 104B
Iepriekšējā atvēršanas cena	43.19
Iepriekšējā slēgšanas cena	43.37

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

51.665 / 52.38 Atbalsts un pretestība

Sanofi Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. apr. 06:12 UTC

Peļņas

Sanofi Posts Higher Sales Amid Leadership Transition

2026. g. 12. febr. 12:40 UTC

Galvenie tirgus virzītāji

Sanofi Shares Fall After CEO Change

2026. g. 29. janv. 11:35 UTC

Peļņas

Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update

2026. g. 29. apr. 12:01 UTC

Peļņas

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

2026. g. 27. apr. 09:32 UTC

Tirgus saruna

Peļņas

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

2026. g. 27. apr. 09:19 UTC

Tirgus saruna

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

2026. g. 23. apr. 05:34 UTC

Peļņas

Sanofi: 2026 Expectations Are at Constant Exchange Rates

2026. g. 23. apr. 05:34 UTC

Peļņas

Sanofi Sees Business EPS Growth Slightly Faster Than Sales in 2026

2026. g. 23. apr. 05:34 UTC

Peļņas

Sanofi Sees Sales Growth by a High Single-Digit Percentage in 2026

2026. g. 23. apr. 05:34 UTC

Peļņas

Sanofi Backs 2026 View

2026. g. 23. apr. 05:33 UTC

Peļņas

Sanofi 1Q Business Net Pft EUR2.26B

2026. g. 23. apr. 05:33 UTC

Peļņas

Analysts Saw Sanofi 1Q Business Oper Pft at EUR2.85B

2026. g. 23. apr. 05:33 UTC

Peļņas

Sanofi 1Q Business Oper Pft EUR2.97B

2026. g. 23. apr. 05:32 UTC

Peļņas

Analysts Saw Sanofi 1Q Net Sales at EUR10.22B

2026. g. 23. apr. 05:32 UTC

Peļņas

Sanofi 1Q Net Sales Rose 14% on Year at Constant Exchange Rates

2026. g. 23. apr. 05:31 UTC

Peļņas

Sanofi 1Q Net Sales EUR10.51B

2026. g. 10. apr. 11:12 UTC

Tirgus saruna

Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

2026. g. 10. apr. 10:54 UTC

Tirgus saruna

Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

2026. g. 30. marts 10:40 UTC

Tirgus saruna

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

2026. g. 27. marts 10:40 UTC

Tirgus saruna

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

2026. g. 11. marts 11:02 UTC

Tirgus saruna

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

2026. g. 24. febr. 14:00 UTC

Iegādes, apvienošanās, pārņemšana

This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug -- Barrons.com

2026. g. 13. febr. 08:21 UTC

Tirgus saruna

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

2026. g. 12. febr. 15:20 UTC

Peļņas

Sanofi Shares Fall After CEO Change -- Update

2026. g. 10. febr. 14:07 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi Set Out $2.2 Bln Cash Deal for Dynavax Late Last Year

2026. g. 10. febr. 14:06 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi: Acquisition Includes Dynavax's Hepatitis B Vaccine, Shingles Vaccine Candidate

2026. g. 10. febr. 14:05 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi Completes Acquisition of Dynavax

2026. g. 10. febr. 14:00 UTC

Iegādes, apvienošanās, pārņemšana

Press Release: Sanofi Completes The Acquisition Of Dynavax >SAN.FR

2026. g. 6. febr. 12:35 UTC

Peļņas

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

2026. g. 29. janv. 13:00 UTC

Tirgus saruna

Peļņas

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

Salīdzinājums

Cenas izmaiņa

Sanofi Prognoze

Cenas mērķis

By TipRanks

22.26% augšup

Prognoze 12 mēnešiem

Vidējais 53 USD 22.26%

Augstākais 57 USD

Zemākais 50 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sanofi — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Sanofi — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

51.665 / 52.38Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.